Group 1 - The core viewpoint of the article highlights that Jingtai Holdings (02228) has successfully delivered an automated workstation for formula stability testing to BASF, enhancing BASF's automation system across sample management, testing analysis, and data management [1] - The stock price of Jingtai Holdings increased by 4.52%, reaching HKD 11.8, with a trading volume of HKD 296 million [1] - The automated platform has been successfully delivered in high-value fields such as new drug development, chemical synthesis, and new material discovery [1] Group 2 - On February 5, Jingtai Holdings announced a project agreement and long-term strategic cooperation with Weisheng Pharmaceutical (02561) [1] - The collaboration aims to integrate Jingtai Holdings' AI and robotics drug development platform with Weisheng Pharmaceutical's expertise in the endocrine field, focusing on high clinical value indications and innovative targets [1] - This partnership seeks to advance the early discovery and clinical translation of innovative therapies in the endocrine treatment sector, targeting a market potential worth hundreds of billions [1]